Evidence map›Paper›PMID 36385202›Full record

ArticleJournal of neurology2023

Motor symptoms in genetic frontotemporal dementia: developing a new module for clinical rating scales.

Kiran Samra, Amy M MacDougall, Georgia Peakman, Arabella Bouzigues, Martina Bocchetta, David M Cash, Caroline V Greaves, Rhian S Convery, John C van Swieten, Lize Jiskoot and 27 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of neurology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.1field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Integrating a motor domain enhances disease severity scales in an FTD-ALS spectrum cohort.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  3. Article
  4. Article
  5. Observational
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

37 authors at 20 institutions in 10 countries.

Kiran SamraDementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, Queen Square, London, WC1N 3BG, UK. k.samra@ucl.ac.uk.ORCID http://orcid.org/0000-0002-3105-7099
Amy M MacDougallDepartment of Medical Statistics, London School of Hygiene and Tropical Medicine, London, UK.
Georgia PeakmanDementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, Queen Square, London, WC1N 3BG, UK.
Arabella BouziguesDementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, Queen Square, London, WC1N 3BG, UK.
Martina BocchettaDementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, Queen Square, London, WC1N 3BG, UK.
David M CashDementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, Queen Square, London, WC1N 3BG, UK.
Caroline V GreavesDementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, Queen Square, London, WC1N 3BG, UK.
Rhian S ConveryDementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, Queen Square, London, WC1N 3BG, UK.
John C van SwietenDepartment of Neurology, Erasmus Medical Centre, Rotterdam, Netherlands.
Lize JiskootDepartment of Neurology, Erasmus Medical Centre, Rotterdam, Netherlands.
Harro SeelaarDepartment of Neurology, Erasmus Medical Centre, Rotterdam, Netherlands.
Fermin MorenoCognitive Disorders Unit, Department of Neurology, Donostia Universitary Hospital, San Sebastian, Spain.
Raquel Sanchez-ValleAlzheimer's Disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clínic, Institut d'Investigacións Biomèdiques August Pi I Sunyer, University of Barcelona, Barcelona, Spain.
Robert LaforceClinique Interdisciplinaire de Mémoire, Département des Sciences Neurologiques, CHU de Québec, and Faculté de Médecine, Université Laval, Quebec City, Quebec, Canada.
Caroline GraffCenter for Alzheimer Research, Division of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society, Bioclinicum, Karolinska Institutet, Solna, Sweden.
Mario MasellisSunnybrook Health Sciences Centre, Sunnybrook Research Institute, University of Toronto, Toronto, Canada.
Carmela TartagliaTanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, ON, Canada.
James B RoweDepartment of Clinical Neurosciences, University of Cambridge, Cambridge, UK.
Barbara BorroniNeurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.
Elizabeth FingerDepartment of Clinical Neurological Sciences, University of Western Ontario, London, ON, Canada.
Matthis SynofzikDepartment of Neurodegenerative Diseases, Hertie-Institute for Clinical Brain Research and Center of Neurology, University of Tübingen, Tübingen, Germany.
Daniela GalimbertiFondazione Ca' Granda, IRCCS Ospedale Policlinico, Milan, Italy.
Rik VandenbergheLaboratory for Cognitive Neurology, Department of Neurosciences, KU Leuven, Leuven, Belgium.
Alexandre de MendonçaLaboratory of Neurosciences, Institute of Molecular Medicine, Faculty of Medicine, University of Lisbon, Lisbon, Portugal.
Chris R ButlerNuffield Department of Clinical Neurosciences, Medical Sciences Division, University of Oxford, Oxford, UK.
Alexander GerhardDivision of Neuroscience and Experimental Psychology, Wolfson Molecular Imaging Centre, University of Manchester, Manchester, UK.
Simon DucharmeDepartment of Psychiatry, McGill University Health Centre, McGill University, Montreal, QC, Canada.
Isabelle Le BerParis Brain Institute-Institut du Cerveau-ICM, Inserm U1127, CNRS UMR 7225, AP-HP-Hôpital Pitié-Salpêtrière, Sorbonne Université, Paris, France.
Pietro TiraboschiFondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
Isabel SantanaNeurology Service, Faculty of Medicine, University Hospital of Coimbra (HUC), University of Coimbra, Coimbra, Portugal.
Florence PasquierUniv Lille, Lille, France.
Johannes LevinDepartment of Neurology, Ludwig-Maximilians Universität München, Munich, Germany.
Markus OttoDepartment of Neurology, University of Ulm, Ulm, Germany.
Sandro SorbiDepartment of Neurofarba, University of Florence, Florence, Italy.
Jonathan D Rohrer *Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, Queen Square, London, WC1N 3BG, UK.
Lucy L Russell *Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, Queen Square, London, WC1N 3BG, UK.
Genetic FTD Initiative (GENFI)
NIHR Queen Square Dementia Biomedical Research Unit · GBErasmus University Rotterdam · NLFondazione IRCCS Istituto Neurologico Carlo Besta · ITUniversity of Coimbra · PTGerman Center for Neurodegenerative Diseases · DEKarolinska University Hospital · SEUK Dementia Research Institute · GBUniversity of Brescia · ITBiogipuzkoa Health Research Institute · ESCentre National de la Recherche Scientifique · FRDon Carlo Gnocchi Foundation · ITInserm · FRLondon School of Hygiene & Tropical Medicine · GBMontreal Neurological Institute and Hospital · CAMunich Cluster for Systems Neurology · DESunnybrook Health Science Centre · CAUniversitat de Barcelona · ESUniversität Ulm · DEUniversité Laval · CAUniversity of Cambridge · GB

Funding

Medical Research Council MR/K010395/1Medical Research Council MR/M008525/1Medical Research Council MR/M023664/1Medical Research Council MR/T046015/1Medical Research Council SUAG/051 G101400Wellcome TrustWellcome Trust 103838
6 · The paper itself

Abstract

objectiveTo investigate the optimal method of adding motor features to a clinical rating scale for frontotemporal dementia (FTD).

methodsEight hundred and thirty-two participants from the international multicentre Genetic FTD Initiative (GENFI) study were recruited: 522 mutation carriers (with C9orf72, GRN and MAPT mutations) and 310 mutation-negative controls. A standardised clinical questionnaire was used to assess eight motor symptoms (dysarthria, dysphagia, tremor, slowness, weakness, gait disorder, falls and functional difficulties using hands). Frequency and severity of each motor symptom was assessed, and a principal component analysis (PCA) was performed to identify how the different motor symptoms loaded together. Finally, addition of a motor component to the CDR

results24.3% of mutation carriers had motor symptoms (31.7% C9orf72, 18.8% GRN, 19.3% MAPT) compared to 6.8% of controls. Slowness and gait disorder were the commonest in all genetic groups while tremor and falls were the least frequent. Symptom severity scores were similar to equivalent physical motor examination scores. PCA revealed that all motor symptoms loaded together so a single additional motor component was added to the CDR

conclusionsMotor features are present in mutation carriers at all disease stages across all three genetic groups. Inclusion of motor symptoms in a rating scale that can be used in future clinical trials will not only ensure a more accurate severity measure is recorded but that a wider spectrum of FTD phenotypes can be included in the same trial.

Indexed as

Amyotrophic Lateral SclerosisFrontotemporal DementiaC9orf72 ProteinHumansMutationtau ProteinsTremorC9orf72 Proteintau ProteinsC9orf72Frontotemporal dementiaGeneticsMotorProgranulinTau

Identifiers

PMID36385202
PMCPMC9971048
OpenAlexW4309149093

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.